Liraglutide effectively addresses weight regain post-bariatric surgery

A randomized, placebo-controlled trial demonstrated that liraglutide 3.0 mg significantly combats weight regain after Roux-en-Y gastric bypass, with 76% of subjects achieving at least a 5% total body weight loss compared to 17% in the placebo group. Notably, 21% of liraglutide recipients exceeded their postoperative nadir weight. Throughout the study, nonserious adverse events were reported in 41.6% of liraglutide users, while serious adverse events occurred less frequently, highlighting its safety profile in this context.